Prostate neuroendocrine neoplasm

This phase 2 trial tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks DNA repair in cancer cells, while cediranib stops tumor blood vessel growth. The study involves 90 particip…

This Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer that has spread. The goal is to see if this treatment can slow or stop tumor growth. About 45 participants…

This early-phase trial tests an investigational drug called ABBV-706, alone or combined with other drugs, in about 288 adults with advanced solid tumors like small cell lung cancer, high-grade brain tumors, and neuroendocrine cancers. The main goals are to check safety, find the …

This study tests a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in 41 men with a hard-to-treat form of prostate cancer. The goal is to see if this mix can slow or stop cancer growth. Participants receive up to 10 cycles of the combo, then contin…

This study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have a specific marker (DLL3). The main goals are to find the safest dose and understand side effects. About 232 adults will tak…

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This study examines 15 proteins on prostate cancer cells from 1,600 patients to see which ones are common and whether they relate to survival. Researchers will analyze stored tissue samples and collect new ones from men with advanced cancer. The goal is to understand these protei…